Business Today
Loading...

Lupin receives two observations from USFDA after Nagpur facility assessment

A Prior Approval Inspection was carried out by the United States Food and Drug Administration at Lupin's Nagpur oral solid dosage manufacturing facility between January 6-10, 2020

twitter-logo PTI        Last Updated: January 11, 2020  | 19:32 IST
Lupin receives two observations from USFDA after Nagpur facility assessment

Drug firm Lupin on Saturday said it has received two observations from the US health regulator following the inspection of its Nagpur manufacturing facility.

A PAI (Prior Approval Inspection) was carried out by the United States Food and Drug Administration (USFDA) at the company's Nagpur oral solid dosage manufacturing facility between January 6-10, 2020, Lupin said in a filing to BSE.

"The inspection closed with two 483 observations," Lupin said.

The USFDA issues observations by means of Form 483 notifying a company's management of objectionable conditions at the facility inspected.

"We are committed to meeting the highest quality standards and are committed to full compliance with CGMP regulations at all our manufacturing facilities. The Nagpur facility is our latest oral solid dosage facility, and this was the seventh USFDA inspection at the facility," Lupin MD Nilesh Gupta said.

Lupin will address the observations raised by the agency satisfactorily and will submit a comprehensive response within the stipulated timeline, he added.

ALSO READ:Global med-tech majors seek custom duty cut to prevent smuggling of medical devices

ALSO READ:USFDA slaps 19 warning letters to Indian pharma firms in 2019; highest in 4 years

Youtube
  • Print

  • COMMENT
BT-Story-Page-B.gif
A    A   A
close